TTC39B deficiency stabilizes LXR reducing both atherosclerosis and steatohepatitis
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index; none of the 33 sources its claims cite is checked for support yet.
Abstract
Cellular mechanisms that mediate steatohepatitis, an increasingly prevalent condition in the Western world for which no therapies are available, are poorly understood. Despite the fact that its synthetic agonists induce fatty liver, the liver X receptor (LXR) transcription factor remains a target of interest because of its anti-atherogenic, cholesterol removal, and anti-inflammatory activities. Here we show that tetratricopeptide repeat domain protein 39B (Ttc39b, C9orf52) (T39), a high-density lipoprotein gene discovered in human genome-wide association studies, promotes the ubiquitination and degradation of LXR. Chow-fed mice lacking T39 (T39−/−) display increased high-density lipoprotein cholesterol levels associated with increased enterocyte ATP-binding cassette transporter A1 (Abca1) expression and increased LXR protein without change in LXR messenger RNA. When challenged with a high fat/high cholesterol/bile salt diet, T39−/− mice or mice with hepatocyte-specific T39 deficiency show increased hepatic LXR protein and target gene expression, and unexpectedly protection from steatohepatitis and death. Mice fed a Western-type diet and lacking low-density lipoprotein receptor (Ldlr−/−T39−/−) show decreased fatty liver, increased high-density lipoprotein, decreased low-density lipoprotein, and reduced atherosclerosis. In addition to increasing hepatic Abcg5/8 expression and limiting dietary cholesterol absorption, T39 deficiency inhibits hepatic sterol regulatory element-binding protein 1 (SREBP-1, ADD1) processing. This is explained by an increase in microsomal phospholipids containing polyunsaturated fatty acids, linked to an LXRα-dependent increase in expression of enzymes mediating phosphatidylcholine biosynthesis and incorporation of polyunsaturated fatty acids into phospholipids. The preservation of endogenous LXR protein activates a beneficial profile of gene expression that promotes cholesterol removal and inhibits lipogenesis. T39 inhibition could be an effective strategy for reducing both steatohepatitis and atherosclerosis.
Overview
CoChat Summary
TL;DR
TTC39B (T39) promotes ubiquitination and degradation of LXR; T39 deficiency stabilizes LXR protein and protects mice from both steatohepatitis and atherosclerosis. The mechanism couples increased cholesterol removal with inhibited SREBP-1 processing and lipogenesis.
Key findings
- T39 deficiency increased HDL cholesterol by ∼22% in chow-fed mice and by 42% after HF/HC/BS diet, with a 45% increase in ApoA-1; this was linked to increased intestinal Abca1 and post-transcriptional LXR protein induction.
- In HF/HC/BS-fed T39−/− mice, there was a 4-fold reduction in mortality (p<0.05), decreased ALT, less hepatic TG and cholesteryl ester accumulation, fewer inflammatory foci, less ballooning, and less fibrosis; protection was due to hepatic T39 deficiency and was LXRα-dependent.
- T39 deficiency inhibited hepatic SREBP-1 processing and reduced lipogenic gene expression and TG synthesis, associated with LXRα-dependent induction of Insig2a, Pcyt1a, Cept1, and Lpcat3, a 30% increase in microsomal phosphatidylcholine, and increased PUFA content in phospholipids.
- In WTD-fed Ldlr−/−T39−/− mice, T39 deficiency decreased fatty liver, increased HDL, decreased LDL, and reduced atherosclerotic lesion area and lesion complexity.
Methods
- Mouse models included whole-body T39−/−, tissue-specific Villin-Cre and Albumin-Cre T39fl/fl, Ldlr−/−T39−/−, and Lxrα−/−T39−/− mice; both sexes, 10–20 weeks old, fed chow, HF/HC/BS diet (7.5% cocoa butter, 1.25% cholesterol, 0.5% sodium cholate), or WTD (21% milk fat, 0.15% cholesterol), with blinded measurements.
- Analyses included lipoprotein/cholesterol/TG assays, Western blotting, gene expression, [3H]cholesterol secretion from enterocytes, NASH histological grading, dietary cholesterol absorption, GC-MS sterol/oxysterol measurement, in vivo lipogenesis, lipidomics, atherosclerosis quantification, ChIP, co-immunoprecipitation, GW3965-affinity LXR pulldown, and LXRα turnover assays.
- Statistics used mean ± SEM, two-tailed Student t-test or two-way ANOVA with Bonferroni post hoc, p<0.05 significance, and Grubbs’ test for outliers.
Limitations
- The paper does not state limitations explicitly. Evident from the text: all functional and therapeutic conclusions come from mouse models and cell culture, with no human interventional or clinical validation.
- Several mechanistic links are proposed rather than fully established; the text notes “there must be a separate more physiologically relevant mechanism regulating SREBP-1 maturation” and that increased PC synthesis/PUFA incorporation “may be a major factor” inhibiting NAFLD.
- No pharmacological T39 inhibitor was tested in vivo; the therapeutic implication that “T39 inhibition could be an effective strategy” remains untested in this paper.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 0 Not valid · 28 Not checked · 128 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The livers of Albumin-Cre(+)T39fl/fl mice had less perisinusoidal and periportal fibrosis compared to the T39fl/fl and Villin-Cre(+)T39fl/fl mice (Fig 1g and ED Fig 4a,b)”
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Main
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The decrease in the mature form of SREBP-1 associated with T39 deficiency was LXRα-dependent (ED Fig 6b).”
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Main
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“When challenged with a high fat/high cholesterol/bile salt (HF/HC/BS) diet, T39-/- mice or mice with hepatocyte-specific T39 deficiency showed increased hepatic LXR protein and target gene expression, and unexpectedly protection from steato-hepatitis and death.”
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Small intestinal enterocytes from chow-fed T39-/- mice showed increased Abca1 mRNA and protein (ED Fig 2d,e and Fig 1a).”
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Main
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“When challenged with a high fat/high cholesterol/bile salt (HF/HC/BS) diet, T39-/- mice or mice with hepatocyte-specific T39 deficiency showed increased hepatic LXR protein and target gene expression, and unexpectedly protection from steato-hepatitis and death.”
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
100 more claims
Create a free account to see all 156 claims and to verify the 33 references still open.
- It may state two separate claims as one. 33
- Probably not a substantial claim. 19
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Main
“the decrease in [3H]-labelled TG observed in Figure 3D”
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Main
“PC, PE and phosphatidylserine PS species all had significantly increased PUFA content (Fig 3d,e,f)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Extended Data
“Hepatic plant sterol content of WT, whole body T39 knockout, LXRα knockout, and LXRα T39 double knockout mice fed HF/HC/BS diet for 6 weeks”
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Extended Data
“n= 4 Lxrα+/+T39+/+, 4 Lxrα+/+T39-/-, 4 Lxrα-/-T39+/+, and 6 Lxrα-/-T39+/+.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Extended Materials > Methods
“Liver cell injury was assigned a score from 0 to 2 as follows:”
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Extended Materials > Methods
“majority of hepatocytes are ballooned = 3.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Main
“T39-/- mice challenged with 3 weeks of the HF/HC/BS diet had a 42% increase in HDL cholesterol levels (ED Fig 2a)”
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Extended Data
“(a) HDL-cholesterol of WT and whole body T39 knockout mice fed chow or HF/HC/BS diet for 4 weeks, n=4 per genotype for chow, 5 per genotype for HF/HC/BS diet.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Extended Data
“Absorption of [14C]cholesterol administered by gavage to WT and whole body T39 knockout with/without LXRα along with Poloxamer-407 injection to inhibit peripheral lipoprotein catabolism”
§ TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis > Extended Data
“n= 3 Lxrα+/+T39+/+, 4 Lxrα+/+T39-/-, 3 Lxrα-/-T39+/+, and 5 Lxrα-/-T39+/+.”
Citations
Cites
A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Stary, H. C., Chandler, A. B., Dinsmore, R. E., Fuster, V., Glagov, S., Insull, W., Rosenfeld, M. E., Schwartz, C. J., Wagner, W. D., & Wissler, R. W. (1995) · Circulation · doi:10.1161/01.cir.92.5.1355 · Cited by 3,533
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487 · cited 2×
“Genome-wide association studies have uncovered a plethora of novel genetic loci associated with alterations in plasma lipoprotein levels 2,3 that have potential to provide insights into metabolic diseases such as atherosclerosis and fatty liver.”
Self-citationGenetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Willer (2013) · doi:10.1038/ng.2797 · Cited by 2,983
Repa, J. J., Liang, G., Ou, J., Bashmakov, Y., Lobaccaro, J.-M. A., Shimomura, I., Shan, B., Brown, M. S., Goldstein, J. L., & Mangelsdorf, D. J. (2000) · Genes & Development · doi:10.1101/gad.844900 · Cited by 1,692
Sterol-dependent Transactivation of theABC1 Promoter by the Liver X Receptor/Retinoid X Receptor
Costet, P., Luo, Y., Wang, N., & Tall, A. R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003337200 · Cited by 979
Self-citationLXR Regulates Cholesterol Uptake Through Idol-Dependent Ubiquitination of the LDL Receptor
Zelcer, N., Hong, C., Boyadjian, R., & Tontonoz, P. (2009) · Science · doi:10.1126/science.1168974 · Cited by 848
Kammoun, H. L., Chabanon, H., Hainault, I., Luquet, S., Magnan, C., Koike, T., Ferré, P., & Foufelle, F. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37007 · Cited by 732 · cited 1×
“Also, LPCAT3 activity ameliorates ER stress 10 , which affects SREBP-1 processing 24 .”
LXR signaling couples sterol metabolism to proliferation in the acquired immune response
Bensinger, S. J., Bradley, M. N., Joseph, S. B., Zelcer, N., Janssen, E. M., Hausner, M. A., Shih, R., Parks, J. S., Edwards, P. A., Jamieson, B. D., et al. (2008) · Cell · doi:10.1016/j.cell.2008.04.052 · Cited by 711
Comparative Lipidomic Analysis of Mouse and Human Brain with Alzheimer Disease
Chan, R. B., Oliveira, T. G., Cortes, E. P., Honig, L. S., Duff, K. E., Small, S. A., Wenk, M. R., Shui, G., & Di Paolo, G. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.274142 · Cited by 630 · cited 2×
“Glycerophospholipids and sphingolipids were separated with normal-phase HPLC as described before 35 , with a few modifications.”
Self-citationYu, L., Li-Hawkins, J., Hammer, R. E., Berge, K. E., Horton, J. D., Cohen, J. C., & Hobbs, H. H. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0216001 · Cited by 596
Dzeletovic, S., Breuer, O., Lund, E., & Diczfalusy, U. (1995) · Analytical Biochemistry · doi:10.1006/abio.1995.1110 · Cited by 570
A Meta-Analysis of Randomized Trials for the Treatment of Nonalcoholic Fatty Liver Disease
Musso, G., Gambino, R., Cassader, M., & Pagano, G. (2010) · Hepatology · doi:10.1002/hep.23623 · Cited by 564
McNeish, J., Aiello, R. J., Guyot, D., Turi, T., Gabel, C., Aldinger, C., Hoppe, K. L., Roach, M. L., Royer, L. J., de Wet, J., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.8.4245 · Cited by 537
Intestinal ABCA1 directly contributes to HDL biogenesis in vivo
Brunham, L. R. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27352 · Cited by 519
Self-citationLipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet
Matsuzawa, N., Takamura, T., Kurita, S., Misu, H., Ota, T., Ando, H., Yokoyama, M., Honda, M., Zen, Y., Nakanuma, Y., et al. (2007) · Hepatology · doi:10.1002/hep.21874 · Cited by 515
A Conserved SREBP-1/Phosphatidylcholine Feedback Circuit Regulates Lipogenesis in Metazoans
Walker, A. K., Jacobs, R. L., Watts, J. L., Rottiers, V., Jiang, K., Finnegan, D. M., Shioda, T., Hansen, M., Yang, F., Niebergall, L. J., et al. (2011) · Cell · doi:10.1016/j.cell.2011.09.045 · Cited by 465
Unsaturated Fatty Acids Down-regulate SREBP Isoforms 1a and 1c by Two Mechanisms in HEK-293 Cells
Hannah, V. C., Ou, J., Luong, A., Goldstein, J. L., & Brown, M. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007273200 · Cited by 448 · cited 2×
“Also, hepatic levels of LXR activation by synthetic agonists has traditionally been associated with hypertriglyceridemia and hepatic steatosis, due to induction of SREBP-1c, the transcription factor that controls lipogenic gene expression 15 .”
Relative contributions by liver and intestine to individual plasma apolipoproteins in the rat.
Wu, A. L., & Windmueller, H. G. (1979) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)50321-5 · Cited by 445
Collins, J. L., Fivush, A. M., Watson, M. A., Galardi, C. M., Lewis, M. C., Moore, L. B., Parks, D. J., Wilson, J. G., Tippin, T. K., Binz, J. G., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm0255116 · Cited by 434
Sterol synthesis in vivo in 18 tissues of the squirrel monkey, guinea pig, rabbit, hamster, and rat
Spady, D. K., & Dietschy, J. M. (1983) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37999-2 · Cited by 411
A feed-forward loop amplifies nutritional regulation of PNPLA3
Huang, Y., He, S., Li, J. Z., Seo, Y.-K., Osborne, T. F., Cohen, J. C., & Hobbs, H. H. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003585107 · Cited by 386 · cited 1×
“…carboxylase α (Acc α ), Glycerol-3-phosphate acyltransferase (Gpat1, Gpam), and Glucose-6-phosphate dehydrogenase (G6pd), as well as Patatin-like phospholipase domain-containing protein 3 (Pnpla3, Adiponutrin), which is an SREBP-1 target implicated in human hepatic steatosis 17,18 (Fig 3b).”
Hishikawa, D., Shindou, H., Kobayashi, S., Nakanishi, H., Taguchi, R., & Shimizu, T. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712245105 · Cited by 364
Rong, X., Albert, C. J., Hong, C., Duerr, M. A., Chamberlain, B. T., Tarling, E. J., Ito, A., Gao, J., Wang, B., Edwards, P. A., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.10.002 · Cited by 317
Insulin-independent regulation of hepatic triglyceride synthesis by fatty acids
Vatner, D. F., Majumdar, S. K., Kumashiro, N., Petersen, M. C., Rahimi, Y., Gattu, A. K., Bears, M., Camporez, J.-P. G., Cline, G. W., Jurczak, M. J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1423952112 · Cited by 235
Boergesen, M., Pedersen, T. Å., Gross, B., van Heeringen, S. J., Hagenbeek, D., Bindesbøll, C., Caron, S., Lalloyer, F., Steffensen, K. R., Nebb, H. I., et al. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06175-11 · Cited by 235
Rong, X., Wang, B., Dunham, M. M., Hedde, P. N., Wong, J. S., Gratton, E., Young, S. G., Ford, D. A., & Tontonoz, P. (2015) · eLife · doi:10.7554/elife.06557 · Cited by 228
Zhang, Y., Breevoort, S. R., Angdisen, J., Fu, M., Schmidt, D. R., Holmstrom, S. R., Kliewer, S. A., Mangelsdorf, D. J., & Schulman, I. G. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59817 · Cited by 213
Hegarty, B. D., Bobard, A., Hainault, I., Ferré, P., Bossard, P., & Foufelle, F. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405067102 · Cited by 208
Lo Sasso, G., Murzilli, S., Salvatore, L., D'Errico, I., Petruzzelli, M., Conca, P., Jiang, Z.-Y., Calabresi, L., Parini, P., & Moschetta, A. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.07.002 · Cited by 189
Primary Cultures of Fully Differentiated and Pure Human Intestinal Epithelial Cells
Perreault, N., & Beaulieu, J. (1998) · Experimental Cell Research · doi:10.1006/excr.1998.4221 · Cited by 155
Tomoyori, H., Kawata, Y., Higuchi, T., Ichi, I., Sato, H., Sato, M., Ikeda, I., & Imaizumi, K. (2004) · Journal of Nutrition · doi:10.1093/jn/134.7.1690 · Cited by 117
Self-citationMechanisms involved in vitamin E transport by primary enterocytes and in vivo absorption
Anwar, K., Iqbal, J., & Hussain, M. M. (2007) · Journal of Lipid Research · doi:10.1194/jlr.m700207-jlr200 · Cited by 114
Self-citationIqbal, J., Anwar, K., & Hussain, M. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301177200 · Cited by 104
Self-citationGijbels, M. J. J., van der Cammen, M., van der Laan, L. J. W., Emeis, J. J., Havekes, L. M., Hofker, M. H., & Kraal, G. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(98)00263-9 · Cited by 75
Diet-dependent cardiovascular lipid metabolism controlled by hepatic LXRα
Lehrke, M., Lebherz, C., Millington, S. C., Guan, H.-P., Millar, J., Rader, D. J., Wilson, J. M., & Lazar, M. A. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.04.005 · Cited by 45
Self-citation
Cited by
Weeks, E. M., Ulirsch, J. C., Cheng, N. Y., Trippe, B. L., Fine, R. S., Miao, J., Patwardhan, T. A., Kanai, M., Nasser, J., Fulco, C. P., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01443-6 · Cited by 349
Hepatic cholesterol transport and its role in non-alcoholic fatty liver disease and atherosclerosis
Li, H., Yu, X.-H., Ou, X., Ouyang, X.-P., & Tang, C.-K. (2021) · Progress in Lipid Research · doi:10.1016/j.plipres.2021.101109 · Cited by 227
Cholesterol transport system: An integrated cholesterol transport model involved in atherosclerosis
Yu, X.-H., Zhang, D.-W., Zheng, X.-L., & Tang, C.-K. (2019) · Progress in Lipid Research · doi:10.1016/j.plipres.2018.12.002 · Cited by 218
Inhibition of ASGR1 decreases lipid levels by promoting cholesterol excretion
Wang, J.-Q., Li, L.-L., Hu, A., Deng, G., Wei, J., Li, Y.-F., Liu, Y.-B., Lu, X.-Y., Qiu, Z.-P., Shi, X.-J., et al. (2022) · Nature · doi:10.1038/s41586-022-05006-3 · Cited by 188
Varin, E. M., Mulvihill, E. E., Beaudry, J. L., Pujadas, G., Fuchs, S., Tanti, J.-F., Fazio, S., Kaur, K., Cao, X., Baggio, L. L., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2018.10.001 · Cited by 138
Metadata
- Authors
- Hsieh, J., Koseki, M., Molusky, M. M., Yakushiji, E., Ichi, I., Westerterp, M., Iqbal, J., Chan, R. B., Abramowicz, S., Tascau, L., Takiguchi, S., Yamashita, S., Welch, C. L., Di Paolo, G., Hussain, M. M., Lefkowitch, J. H., Rader, D. J., & Tall, A. R.
- Affiliations
- Columbia University (US)
- Ochanomizu University (JP)
- SUNY Downstate Health Sciences University (US)
- University of Pennsylvania (US)
- The University of Osaka (JP)
- Corresponding author
- Koseki, Masahiro
- Tall, Alan R.
- ORCID
- Venue
- Nature
- Published
- 2016-07
- Volume
- 535
- Issue
- 7611
- Pages
- 303-307
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4947007
- OpenAlex
- W2462155612
- Semantic Scholar
- ee2839ddad345c5575b31795e9c4343879125fb3
- Cited by
- 106
- References
- 38
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 12 · 2023: 8 · 2022: 6 · 2021: 22 · 2020: 13 · 2019: 6 · 2018: 10 · 2017: 8 · 2016: 3
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- Japan Society for the Promotion of Science (15K16203)
- National Heart, Lung, and Blood Institute (RC2HL101864, R01HL119830, P01HL087123, R01HL111398, HL007343, T32HL007343)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK046900, DK-46900, R56DK046900, R29DK046900)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- liver X receptor, atherosclerosis, steatohepatitis, non-alcoholic fatty liver disease, HDL cholesterol, ABCA1, ABCG5/8, dietary cholesterol absorption, SREBP1, Western diet
- MeSH terms
- ATP Binding Cassette Transporter, Subfamily G, Member 5, ATP Binding Cassette Transporter, Subfamily G, Member 8, Liver X Receptors, Animals, Bile Acids and Salts, Cholesterol, Dietary, Fatty Acids, Unsaturated, Fatty Liver, Female, Gene Expression Regulation, Ligands, Lipoproteins, Lipoproteins, HDL, Cholesterol, HDL, Lipoproteins, LDL, Male, Phosphatidylcholines, Receptors, LDL, ATP-Binding Cassette Transporters, Hepatocytes, Lipogenesis, Atherosclerosis, Mice, Sterol Regulatory Element Binding Protein 1, Ubiquitination, Protein Stability, Orphan Nuclear Receptors, Diet, High-Fat, Proteolysis, ATP Binding Cassette Transporter 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.